Journal article

A Clinical Staging Model for Early Intervention Youth Mental Health Services

Shane PM Cross, Daniel F Hermens, Elizabeth M Scott, Antonia Ottavio, Patrick D McGorry, Ian B Hickie

Psychiatric Services | AMER PSYCHIATRIC PUBLISHING, INC | Published : 2014


Transformational reforms in mental health services are providing more young Australians who experience mental health problems with access to high-quality care. However, the current diagnostic approach has low utility in the early stages of illness, causing uncertainty among clinicians in regard to matching clients' needs with safe and effective interventions. The authors propose a clinical staging model that has the potential to better match illness stage to intervention. The model allows clinicians to provide more personalized and responsive care, especially to young people with attenuated syndromes (subthreshold disorders) who have a clear need for mental health care but who may not otherw..

View full abstract


Awarded by National Health and Medical Research Council

Funding Acknowledgements

Funding for the headspace project comes from the Australian Government Department of Health and Ageing. The evaluation of these services was supported by an Australia Fellowship (464914) from the National Health and Medical Research Council to Prof. Hickie. Dr. Hermens is supported by a grant from the New South Wales Ministry of Health, Mental Health and Drug and Alcohol Office. Funding agencies had no role in the protocol design, report writing, and the decision to submit the report for publication.Dr. Hermens has received honoraria from Janssen-Cilag. Dr. Scott has received honoraria from Eli Lilly and Company and Servier and has served on an advisory board for Pfizer. Prof. McGorry has received research funds from AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, and Janssen-Cilag. Prof. Hickie has served as a consultant or advisor for AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Janssen-Cilag, Roche, and Pfizer and has received honoraria from Pfizer, Servier, and AstraZeneca. The other authors report no competing interests.